Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trebst

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 17, 2021
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum DisordersMarius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
Annals of Neurology|December 12, 2023
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnkelien Duchow, Judith Bellmann-Strobl, Tim Friede, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 17, 2021
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum DisordersMarius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 20